Implicity solutions were designed to enable easier and effective remote patient monitoring and foster medical research & innovation

The page discusses recent expert recommendations for remote monitoring of cardiovascular implantable electronic devices and their potential staffing implications for healthcare organizations.

Implicity conducted the EVIDENCE-RM retrospective study on the medical-economic impact of remote monitoring for patients with implantable cardiac defibrillators.

Implicity says its cloud-based AI algorithm filters 61.6% of false positives while maintaining 98.3% sensitivity, in addition to manufacturer AI filtering, according to new HRS data on next-generation ILRs.

The company is seeking results-driven talent.

The page discusses transparency and compliance in healthcare AI marketing and says AI and machine learning have changed how medical conditions are diagnosed, treated, and managed.

The page compares alert-based and non-alert-based platforms for remote monitoring of cardiac implantable electronic devices. Non-alert-based platforms regularly collect and transmit device data for clinicians to review during scheduled check-ups.

The page provides a form for contacting the company with questions or requests for information.

Implicity offers an AI-based remote monitoring solution intended to improve patient care.

The privacy policy applies when visitors use the website or contact the company by email or through the contact form.

Implicity, a Paris-based provider of an AI-driven cardiac remote monitoring platform, raises $40 million in funding led by IRIS, with participation from Five Arrows.

Sep 2026FinSMEsNews article

Implicity secures a $40 million growth equity round led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co. The company plans to use the funding to accelerate U.S. commercial expansion and continue developing its FDA-cleared AI remote cardiac monitoring platform.

Sep 2026Nation's Law Review (GlobeNewswire)News article

Implicity raises €35 million ($40 million) in growth equity to expand its AI-driven cardiac remote monitoring platform in the United States. European growth fund IRIS leads the round alongside Five Arrows, the alternative-assets arm of Rothschild & Co; the funding is intended to support Implicity’s U.S. commercial expansion.

Sep 2026IRISNews article

Implicity reports data at Heart Rhythm Society 2026 showing its next-generation ILR ECG Analyzer reclassifies 61.6% of false-positive alerts in AI-equipped loop recorders while maintaining 98.3% sensitivity. The results extend earlier EHRA findings and show further false-alert reduction after manufacturer AI filtering.

Apr 2026ImplicityNews article